Nanomicelles: An emerging platform for drug delivery to the eye

Therapeutic Delivery

Volumn 4, Issue 1, 2013, Pages 1-3

  Vadlapudi, Aswani Dutt ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

anterior chamber; barriers and pathways; delivery; nanomicelles; posterior chamber; topical

Indexed keywords

AGENTS ACTING ON THE EYE; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; EYE DROPS; LIPOSOME; MACROGOL; NANOPARTICLE; OCTOXINOL; SURFACTANT; UNCLASSIFIED DRUG; VOCLOSPORIN;

ANATOMY; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; COLLOID; CONJUNCTIVA; CORNEA EPITHELIUM; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY EYE; EYE DISEASE; EYELID REFLEX; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROPHOBICITY; INTRAOCULAR DRUG ADMINISTRATION; MICELLE; NANOMICELLE; NANOPHARMACEUTICS; NANOTECHNOLOGY; PATIENT COMPLIANCE; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL SYSTEM FUNCTION;

EID: 84871581004     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.122     Document Type: Review

References (15)

1. Vadlapudi AD, Patel A, Cholkar K, Mitra AK. Recent patents on emerging therapeutics for the treatment of glaucoma, age related macular degeneration and uveitis. Recent Patents Biomedical Engineering 5(1), 83-101 (2012).
2. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 7(4), E820-E833 (2005).
3. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Patents Nanomedicine 2(2), 82-95 (2012).
4. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 12(3), 348-360 (2010).
5. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm. Res. 26(5), 1197-1216 (2009).
6. Velagaleti PR, Anglade E, Khan IJ, Gilger BC, Mitra AK. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye. Drug Deliv. Technol. 10(4), 42-47 ( 2010).
7. Vadlapudi AD, Vadlapatla RK, Mitra AK. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents. Recent Pat. Antiinfect. Drug Discov. 7(1), 8-18 (2012).
8. Fischer N, Narayanan R, Loewenstein A, Kuppermann BD. Drug delivery to the posterior segment of the eye. Eur. J. Ophthalmol. 21(S6), 20-26 (2010).
9. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 13(3-4), 135-143 (2008).
10. Booth BA, Vidal Denham L, Bouhanik S, Jacob JT, Hill JM. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 24(7), 581-602 (2007).
11. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57(14), 2010-2032 (2005).
12. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond. ) 5(3), 485-505 (2010).
13. Loftsson T, Sigurdsson HH, Konradsdottir F, Gisladottir S, Jansook P, Stefansson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 63(3), 171-179 (2008).
14. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24(1), 1-16 (2007).
15. Komai Y, Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest. Ophthalmol. Vis. Sci. 32(8), 2244-2258 (1991).